Results 211 to 220 of about 2,715,906 (243)

Characterisation of the Novel HLA-C*07:01:139 Allele by Sequencing-Based Typing. [PDF]

HLA
Pajot T, Top I, Blois M, Cremoni M, Elsermans V.   +4 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Genomic Confirmation of HLA-DQA1*01:67:01 by Next Generation Sequencing and Oxford Nanopore Sequencing. [PDF]

HLA
Merschman J, Benidt D, Kreuter J, Wakefield L, Gandhi MJ.   +4 more
europepmc   +1 more source

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

Integrating Heterogeneous Real-World Cancer Data for Semantic Interoperability in Oncology and Medical Imaging: Development and Validation of the Cancer Image Europe Hyperontology. [PDF]

J Med Internet Res
El Ghosh M, Kalokyri V, Bobowicz M, Sambres M, Vaterkowski M, Giraldo O, Charlet J, Fournier L, Duclos C, Tannier X, Tsakou G, Tsiknakis M, Dhombres F, Daniel C.   +13 more
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

The Full Genomic Sequence of the HLA-DQB1*06:524 Allele Identified Using PacBio Sequencing. [PDF]

HLA
Li Z, Hu S, Yang S, Zhang J.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

The Novel HLA-B*78:04:02 Allele Identified in Patient and His Sibling. [PDF]

HLA
Loginova M, Morozova N, Paramonov I.
europepmc   +1 more source

The Identification of the Novel HLA-B*18:01:01:98 Allele in an Individual From Western India. [PDF]

HLA
Rajak J, Tambe M, Firfire A, D'Silva SZ.
europepmc   +1 more source